Celldex Therapeutics reported $426.56M in Current Assets for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Amgen AMGN:US $ 24380M 5281M
Applied Genetic Technologies AGTC:US $ 93.39M 16.32M
Aptinyx Inc APTX:US $ 132.41M 1.37M
Arena Pharmaceuticals ARNA:US $ 790.92M 199.52M
Biocept BIOC:US $ 47.26M 11.29M
Bristol Myers Squibb BMY:US $ 31443M 2282M
Celldex Therapeutics CLDX:US $ 426.56M 258.95M
Cytrx CYTR:US 16.55M 7.79M
Glaxosmithkline GSK:US $ 18254M 688M
Immunogen IMGN:US $ 296.8M 22.41M
Merrimack Pharmaceuticals MACK:US $ 16.54M 2.14M
Nektar Therapeutics NKTR:US $ 986.14M 70.01M
Newlink Genetics NLNK:US 105.75M 7.72M
Northwest Biotherapeutics NWBO:US 6.31M 2.04M
Rigel Pharmaceuticals RIGL:US $ 171.1M 13.09M
Seattle Genetics SGEN:US $ 3114.61M 16.1M